Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head office: Sakyo-ku, Kyoto; Representative Director: Koji Murota)note (supplementary information) symbolInnovation Kyoto 2016 Investment Limited Partnership ("KYOTO-iCAP No. 1 Fund"), with KYOTO-iCAP No. 1 as its general partner, has made an investment in Kinopharma Co. (Head Office: Chuo-ku, Tokyo; Representative Director: Masashi Kikuroishi Suzuki).

Execution of Investment in Kino Pharma, Inc.
Kinopharma is a company engaged in the research and development of FIT-039, an innovative next-generation antiviral drug candidate compound discovered through joint research with Kyoto University Graduate School of Medicine, Department of Morphogenetic Mechanisms (Professor Masatoshi Hagiwara) and Tokyo Medical and Dental University.

An investigator-initiated clinical trial of FIT-039 for verruca vulgaris is ongoing at Kyoto University Hospital. Kinopharma supports this clinical trial and is also expanding the indications and licensing activities for FIT-039.

Kyoto iCAP has evaluated the potential contribution to patients of FIT-039, which was researched and developed at Kyoto University, as well as the potential for FIT-039 to be applied to a wide range of diseases caused by various viruses, both systemic and localized, and has responded to a third-party allocation of new shares to Kinopharma, together with MBIL Venture Capital Co. (Head office: Nagoya, Japan; Representative Director: Yasuyo Katsurayama), and on December 26, Kino invested 150 million yen in Kinopharma.

Outline of Kino Pharma Co.

Establishment	April 11, 2005
Business	Research, development, and provision of novel small molecule clinical drugs targeting protein phosphatases (kinases)
Head Office Location	Chuo-ku, Tokyo
President & CEO	Takashi Suzuki / Masashi Kuroishi